Biotechnology The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) today granted conditional marketing authorization for Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), developed by USA-based Vertex Pharmaceuticals and Swiss firm CRISPR Therapeutics. 16 November 2023